Frequency Therapeutics, Inc. FREQ NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

42/100

2/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Frequency Therapeutics, Inc. (FREQ) generated $-78.56M in operating cash flow for fiscal year 2025. After capital expenditures of $518K, free cash flow was $-79.08M.

Free cash flow margin was -1237.2% of revenue. Cash conversion ratio was 0.67x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (75/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (0/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 0.67x suggests some earnings are non-cash items

Overall SharesGrow Score: 42/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

42/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

FUTURE

52/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

75/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

0/100

Proven by this page

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Frequency Therapeutics, Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-78.56M	$-78.56M	$-60.07M	$-67.28M	$-58.24M
Capital Expenditure	$-518K	$-518K	$-17.9M	$-7.84M	$0.00
Free Cash Flow	$-79.08M	$-79.08M	$-77.98M	$-75.12M	$-58.24M